Merck & Co Inc
MRK106.850USD
+0.400+0.38%
종가 12/26, 16:00（ET）시세는 15분 지연됩니다
265.77B시가총액
14.10P/E TTM
자세한 내용은 Merck & Co Inc 회사
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
Merck & Co Inc 정보
종목 코드 MRK
회사 이름Merck & Co Inc
상장일Feb 06, 2077
CEODavis (Robert M)
직원 수75000
유형Ordinary Share
회계 연도 종료Feb 06
주소126 East Lincoln Avenue
도시RAHWAY
증권 거래소NASDAQ OMX NASDAQ Basic NYSE
국가United States of America
우편 번호07065
전화19087404000
웹사이트https://www.merck.com/
종목 코드 MRK
상장일Feb 06, 2077
CEODavis (Robert M)
Merck & Co Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
85.34K
+28.11%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
Ms. Patricia F. Russo
Ms. Patricia F. Russo
Independent Director
Independent Director
13.15K
--
Mr. Thomas Henry (Tom) Glocer, J.D.
Mr. Thomas Henry (Tom) Glocer, J.D.
Lead Independent Director
Lead Independent Director
5.10K
--
Mr. Inge G. Thulin
Mr. Inge G. Thulin
Independent Director
Independent Director
2.93K
--
Ms. Pamela J. Craig
Ms. Pamela J. Craig
Independent Director
Independent Director
1.72K
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
85.34K
+28.11%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
수익 분석
통화: USD마지막 업데이트: Mon, Oct 6
통화: USD마지막 업데이트: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Oncology-Keytruda
7.96B
50.34%
Vaccines -Gardasil/Gardasil
1.13B
7.12%
Animal Health-Livestock
961.00M
6.08%
Animal Health-Companion Animals
685.00M
4.33%
Vaccines -ProQuad/M-M-R II/Varivax
609.00M
3.85%
기타
4.47B
28.27%
지역별USD
이름
수익
비율
United States
8.84B
55.90%
Europe, Middle East and Africa
3.66B
23.15%
Latin America
859.00M
5.43%
Asia Pacific (Other than China and Japan)
785.00M
4.97%
Japan
626.00M
3.96%
기타
1.04B
6.59%
사업별
지역별
사업별USD
이름
수익
비율
Oncology-Keytruda
7.96B
50.34%
Vaccines -Gardasil/Gardasil
1.13B
7.12%
Animal Health-Livestock
961.00M
6.08%
Animal Health-Companion Animals
685.00M
4.33%
Vaccines -ProQuad/M-M-R II/Varivax
609.00M
3.85%
기타
4.47B
28.27%
주식 보유 통계
마지막 업데이트: Mon, Nov 17
마지막 업데이트: Mon, Nov 17
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
10.11%
BlackRock Institutional Trust Company, N.A.
5.69%
State Street Investment Management (US)
4.76%
Wellington Management Company, LLP
3.03%
Geode Capital Management, L.L.C.
2.41%
기타
74.00%
주주
주주
비율
The Vanguard Group, Inc.
10.11%
BlackRock Institutional Trust Company, N.A.
5.69%
State Street Investment Management (US)
4.76%
Wellington Management Company, LLP
3.03%
Geode Capital Management, L.L.C.
2.41%
기타
74.00%
주주 유형
주주
비율
Investment Advisor
42.31%
Investment Advisor/Hedge Fund
26.78%
Research Firm
3.18%
Pension Fund
2.51%
Bank and Trust
2.21%
Sovereign Wealth Fund
1.55%
Hedge Fund
1.06%
Insurance Company
0.69%
Family Office
0.13%
기타
19.59%
기관 주식 보유
마지막 업데이트: Wed, Oct 1
마지막 업데이트: Wed, Oct 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q3
5358
2.02B
81.35%
-45.75M
2025Q2
5398
2.02B
80.82%
-16.42M
2025Q1
5446
2.05B
81.47%
-3.32M
2024Q4
5410
2.04B
80.88%
+11.87M
2024Q3
5200
2.01B
79.47%
-7.96M
2024Q2
5181
2.01B
79.28%
-4.86M
2024Q1
5154
2.00B
78.88%
-6.10M
2023Q4
5065
1.99B
78.60%
+584.81K
2023Q3
4871
1.98B
78.17%
-32.03M
2023Q2
4864
2.00B
78.94%
-18.54M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
251.75M
10.08%
+356.59K
+0.14%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
142.78M
5.72%
-4.51M
-3.06%
Jun 30, 2025
State Street Investment Management (US)
118.49M
4.74%
-2.04M
-1.69%
Jun 30, 2025
Wellington Management Company, LLP
76.86M
3.08%
-4.81M
-5.89%
Jun 30, 2025
Geode Capital Management, L.L.C.
58.95M
2.36%
-704.59K
-1.18%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
53.87M
2.16%
+4.64M
+9.42%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
36.11M
1.45%
+1.13M
+3.23%
Jun 30, 2025
Fidelity Management & Research Company LLC
28.48M
1.14%
+229.47K
+0.81%
Jun 30, 2025
Fisher Investments
25.01M
1%
+567.90K
+2.32%
Jun 30, 2025
BlackRock Asset Management Ireland Limited
22.79M
0.91%
+764.14K
+3.47%
Jun 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
VanEck Pharmaceutical ETF
16.09%
FT Vest DJIA Dogs 10 Target Income ETF
10.79%
First Trust NASDAQ Pharmaceuticals ETF
7.94%
Invesco Dow Jones Industrial Average Dividend ETF
6.94%
First Trust Morningstar Dividend Leaders Index Fund
5.39%
Coastal Compass 100 ETF
5.13%
Invesco Pharmaceuticals ETF
4.96%
VanEck Morningstar Wide Moat Value ETF
4.73%
Vaneck Durable High Dividend ETF
4.65%
Franklin Income Focus ETF
4.56%
더 보기
VanEck Pharmaceutical ETF
비율16.09%
FT Vest DJIA Dogs 10 Target Income ETF
비율10.79%
First Trust NASDAQ Pharmaceuticals ETF
비율7.94%
Invesco Dow Jones Industrial Average Dividend ETF
비율6.94%
First Trust Morningstar Dividend Leaders Index Fund
비율5.39%
Coastal Compass 100 ETF
비율5.13%
Invesco Pharmaceuticals ETF
비율4.96%
VanEck Morningstar Wide Moat Value ETF
비율4.73%
Vaneck Durable High Dividend ETF
비율4.65%
Franklin Income Focus ETF
비율4.56%
주식 배당금
지난 5년 동안 총
35.12B
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
Nov 18, 2025
MRK.NB Interim Cash Dividend of gross USD 0.85 paid on Jan 08, 2026 going ex on Dec 15, 2025
Dec 15, 2025
Jan 08, 2026
Dec 15, 2025
Jul 22, 2025
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Oct 07, 2025 going ex on Sep 15, 2025
Sep 15, 2025
Oct 07, 2025
Sep 15, 2025
May 27, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Jul 08, 2025 going ex on Jun 16, 2025
Jun 16, 2025
Jul 08, 2025
Jun 16, 2025
Jan 28, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025
Mar 17, 2025
Apr 07, 2025
Mar 17, 2025
Nov 19, 2024
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024
Dec 16, 2024
Jan 08, 2025
Dec 16, 2024
Jul 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024
Sep 16, 2024
Oct 07, 2024
Sep 16, 2024
May 29, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024
Jun 17, 2024
Jul 08, 2024
Jun 17, 2024
Jan 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Apr 05, 2024
Mar 14, 2024
Nov 28, 2023
MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023
Dec 15, 2023
Jan 08, 2024
Dec 14, 2023
Jul 25, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Oct 06, 2023
Sep 14, 2023
더 보기
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
자주 묻는 질문
Merck & Co Inc의 상위 5대 주주는 누구인가요?
Merck & Co Inc의 상위 5대 주주는 다음과 같습니다:
The Vanguard Group, Inc.는 251.75M주의 주식을 보유하고 있으며, 전체 주식의 10.08%를 차지합니다.
BlackRock Institutional Trust Company, N.A.는 142.78M주의 주식을 보유하고 있으며, 전체 주식의 5.72%를 차지합니다.
State Street Investment Management (US)는 118.49M주의 주식을 보유하고 있으며, 전체 주식의 4.74%를 차지합니다.
Wellington Management Company, LLP는 76.86M주의 주식을 보유하고 있으며, 전체 주식의 3.08%를 차지합니다.
Geode Capital Management, L.L.C.는 58.95M주의 주식을 보유하고 있으며, 전체 주식의 2.36%를 차지합니다.
The Vanguard Group, Inc.는 251.75M주의 주식을 보유하고 있으며, 전체 주식의 10.08%를 차지합니다.
BlackRock Institutional Trust Company, N.A.는 142.78M주의 주식을 보유하고 있으며, 전체 주식의 5.72%를 차지합니다.
State Street Investment Management (US)는 118.49M주의 주식을 보유하고 있으며, 전체 주식의 4.74%를 차지합니다.
Wellington Management Company, LLP는 76.86M주의 주식을 보유하고 있으며, 전체 주식의 3.08%를 차지합니다.
Geode Capital Management, L.L.C.는 58.95M주의 주식을 보유하고 있으며, 전체 주식의 2.36%를 차지합니다.
Merck & Co Inc의 상위 3대 주주 유형은 무엇인가요?
Merck & Co Inc의 주요 주주 유형 상위 3가지는
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)입니다.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)입니다.
Merck & Co Inc(MRK)의 주식을 보유한 기관은 몇 개입니까?
2025Q3 기준으로, Merck & Co Inc의 주식을 보유한 기관은 총 5358곳이며, 이들이 보유한 주식의 총 가치는 약 2.02B로 전체 발행 주식의 81.35%를 차지합니다. 이는 2025Q2 대비 0.53% 증가한 수치입니다.
Merck & Co Inc의 최대 수익원은 무엇인가요?
FY2025Q2 기준, Merck & Co Inc의 Oncology-Keytruda 부문이 가장 높은 매출을 기록했으며, 금액은 7.96B로 전체 매출의 50.34%를 차지했습니다.
